A website to provide support for people who have or have had any type of cancer, for their caregivers and for their family members.
Results 1 to 2 of 2

Thread: New dual therapy considered with TNF inhibitor

  1. #1

    New dual therapy considered with TNF inhibitor

    With fewer side effects than traditional chemotherapy, the new treatment is set to move into a phase 2 human clinical trial within 12 months.

    Much recent work has been done to reveal the role of epidermal growth factor receptor (EGFR) in lung cancers. New drugs that inhibit EGFR have been developed, and approved for use, to treat non-small cell lung cancers (NSCLCs) but they have frustratingly displayed limited efficacy, often only working 10 to 15 percent of the time.

    "There has been a tremendous effort over the past several years to block EGFR as a treatment for lung cancer, but this therapy only works in a small subset of patients," explains Amyn Habib, senior author on the new research. "The cancer fights back with a bypass pathway."

    Tracking down and blocking that "bypass pathway" has been fundamental to the new research from Habib and his team. The researchers found that when EGFR is blocked, levels of another protein called tumor necrosis factor (TNF) rise. So it seemed reasonable to explore whether EGFR inhibitors would be more effective in treating lung cancer when paired with TNF inhibitors.

    In an animal study the researchers found that non-small cell lung cancers were much more sensitive to EGFR inhibitors when TNF was blocked. In these early experiments the researchers used a drug called thalidomide as the primary TNF inhibitor. While thalidomide certainly has a controversial history, it has recently been undergoing new evaluation as a useful anti-cancer agent.

    As both drugs are already approved for human use by the FDA it is hoped a phase 2 human clinical trial of the new dual-drug treatment can be fast-tracked. The proposed clinical trial will not only encompass lung cancer patients but also those with glioblastomas, another cancer known to be associated with EGFR.

    "If this strategy is effective, then it might be broadly applicable not only against lung cancer but also against other cancers that express EGFR, which include brain, colon, and head and neck cancers," says David Gerber, an oncologist set to lead the upcoming clinical trial.

    The new research was published in The Journal of Clinical Investigation.

  2. #2
    That's interesting. I'm on a tnf inhibitor Humira for Crohn's and was on remicade which is also a tnf inhibitor before that. They are used for a few different autoimmune disorders.


Similar Threads

  1. Dual FLT3 Mutation
    By MarqueLarsen in forum Leukemia/Myelodysplastic Syndrome Forum
    Replies: 8
    Last Post: 07-22-2015, 08:25 PM
  2. Anti TNF Therapy & Lymphoma
    By pdw1977 in forum Lymphoma - Hodgkin's and Non-Hodgkin's Lymphoma Forum
    Replies: 19
    Last Post: 01-01-2009, 08:58 PM
  3. Is laser therapy considered "Alternative"?
    By discoclub in forum Complementary Therapies
    Replies: 27
    Last Post: 07-06-2007, 05:45 PM
  4. Replies: 0
    Last Post: 08-23-2005, 04:00 AM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts